Actualités de Irvine, California and Amsterdam

Filtre
  • 24.10.2011 – 09:38

    Agendia B.V.

    Agendia Appoints New CEO and Supervisory Board Member

    Irvine, California and Amsterdam (ots/PRNewswire) - Agendia, an innovative molecular diagnostics company, today announced that its supervisory board of directors has appointed David Macdonald as chief executive officer. This follows the resignation of the company's co-founder and chief executive officer, Dr. Bernhard Sixt. Dr. Sixt will remain with the company in an advisory capacity. Agendia also announced the addition ...

  • 18.10.2011 – 15:03

    Agendia B.V.

    EORTC, BIG, and Agendia Announce Completion of Patient Recruitment for International MINDACT Study

    BRUSSELS, IRVINE, California, and AMSTERDAM, October 18, 2011 (ots/PRNewswire) -- The EORTC, BIG, and Agendia, a commercial-stage molecular cancer diagnostics company, today announced the completion of patient registration for the EORTC 10041/BIG3-04 MINDACT (Microarray In Node negative and 1-3 positive lymph node Disease may Avoid Chemotherapy Trial) study. More than ...

  • 03.10.2011 – 15:03

    Agendia B.V.

    Agendia Successfully Completes Bi-Annual FDA Inspection

    Irvine, California and Amsterdam (ots/PRNewswire) - Agendia, an innovative molecular cancer diagnostics company, today announced that the company successfully completed a recent, routine inspection of its Irvine, California-based laboratories by the US Food and Drug Administration (FDA). Agendia received FDA 510(k) clearance for its MammaPrint(R) breast cancer recurrence test in early 2007. It remains the first and only ...

  • 19.09.2011 – 15:09

    Agendia B.V.

    Breast Cancer Research and Treatment Highlights Development and Validation of BluePrint®

    Irvine, California and Amsterdam (ots/PRNewswire) - - Peer-Reviewed Article Notes That Multi-Gene Subtyping Profile Provides Deeper Insight Into Breast Cancer Agendia, an innovative molecular cancer diagnostics company, today announced that a published report highlighting the development and validation of its 80-gene BluePrint breast cancer profile was published online ...